Sanofi Jumps 6% as Raised Outlook and Bigger-Deal Hints Lift Shares
Sanofi shares rose nearly 6% after the drugmaker lifted its 2026 outlook and its CFO said it could pursue deals larger than usual.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Sanofi (SNY) shares climbed nearly 6% on Friday after the drugmaker raised its 2026 outlook and signaled it is open to larger acquisitions, according to GuruFocus.
The company now expects sales to rise by the low teens this year, with business earnings per share growing in the mid-teens at constant exchange rates. Third-quarter sales rose 14.3% to 14.44 billion, and operating income reached 5.43 billion. Dupixent remained the main growth engine, with its sales up 34.8% to 5.7 billion, while new medicines added 1.4 billion.
The bigger surprise came from CFO Francois Roger, who said the company could consider deals above its usual range of 2 to 5 billion dollars. Sanofi continues to focus on immunology, rare diseases and vaccines.
why it matters
The signal matters on two fronts: Sanofi is showing growth today while laying groundwork for its next drivers, since its reliance on Dupixent will eventually need to diminish. If larger deals materialize, investors will focus on their price and how quickly they could accelerate the company's growth.
market impact
Sanofi shares: stronger results and a higher outlook support the stock
- Sanofi shares pressure up — raised outlook and strong third-quarter sales
tags
instruments
sources
- Sanofi Jumps 6% as New CEO Opens Door to Bigger Deals — gurufocus.com, 30 October 2026 at 19:07 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗